Skip to content

Nerve Burial for Preventing Neuralgia After Total Knee Arthroplasty

Saphenous Nerve Brach Burial for Preventing Neuralgia After Total Knee Arthroplasty: A Randomized Controlled Trial

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02885467
Enrollment
58
Registered
2016-08-31
Start date
2013-08-31
Completion date
2018-05-31
Last updated
2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuralgia, Osteoarthritis of the Knee

Keywords

Total Knee Arthroplasty

Brief summary

This is a randomized study investigating whether identification, ligation, and burial of superficial branches of the saphenous nerve crossing the surgical field during total knee arthroplasty reduces the rate of post-operative anterior knee pain and neuralgia compared to standard total knee arthroplasty.

Detailed description

Anterior knee pain is common after total knee arthroplasty. The incision necessarily travels through the path of a cutaneous nerve - branches of the saphenous nerve. Historically, no effort has been made to separate these branches and bury them away from the surgical scar. It has been noted that some patients develop a painful neuroma, that once resected results in a pain free knee. Investigators are trying to study if identification, ligation, and proper burial of the nerve can prevent the development of neuralgia compared to the typical surgical approach which ignores the nerve branches completely.

Interventions

PROCEDURETotal knee arthroplasty with Saphenous nerve burial

Sponsors

Medstar Health Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Must have symptomatic knee osteoarthritis under consideration for total knee arthroplasty * Must be willing to undergo randomization

Exclusion criteria

* Age \<18 or \>80 years * Known pre-operative diagnosis of neuralgia, complex regional pain syndrome, or neuropathy, about the operative lower extremity * Known pre-operative psychiatric disorder requiring medication * Previous surgery about the operative knee * BMI \> 40 kg/m2 (potential increased risk of soft tissue dissection through adipose) * Ongoing pre-operative narcotic use in excess of 20 mg morphine equivalents per day for at least one month or pre-operative intravenous drug use (increased potential for complex regional pain syndrome and neuralgia, increased likelihood to require greater post-operative analgesia) * Ongoing pre-operative use of neuropathic pain medications (gabapentin, pregabalin, amitriptyline, etc.) * Medical comorbidities (American Society of Anesthesiologists grade \> 3 or deemed unfit by consulting internist) precluding elective TKA * Significant language barrier (reading comprehension less than 8th grade reading level) or mental condition precluding accurate self-assessment of knee pain or function. * Severe medication allergies to permissible post-operative analgesics (acetaminophen, tramadol, oxycodone, oxycontin, dilaudid)

Design outcomes

Primary

MeasureTime frameDescription
Incidence of neuralgia2 yearsMeasured by DN4 validated scoring tool

Secondary

MeasureTime frameDescription
Oxford Knee Score2 years
Kneeling weight2 yearsAbility to kneel with body weight on affected knee

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026